Alzheimer’s drug from Eli Lilly wins backing of FDA committee

An advisory committee to the Food and Drug Administration on Monday endorsed an Alzheimer’s drug made by Eli Lilly, setting the stage for the agency to approve another medication that has shown it can slow the progression of the disease.

“I do believe we need to think responsibly if this medicine is going to come to market, because there are risks associated,” said Sarah Dean, the panel’s consumer representative. Eli Lilly shares rose 1.8 percent Monday, as panel members voted. Still, donanemab is unlikely to be an instant blockbuster, according to Wall Street analysts. David Risinger, an analyst at Leerink Partners, said in a research note Sunday that the drug has a “questionable competitive profile.”A key feature of Eli Lilly’s approach is that treatment with the drug could be discontinued once a patient’s amyloid levels are reduced to a certain level.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Source: dcexaminer - 🏆 6. / 94 Read more »

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »